Get to know our clinical trials

Trial of dupilumab in adult patients with bullous pemphigoid.

THE MAIN OBJECTIVE OF THIS STUDY IS TO INVESTIGATE WHETHER DUPILUMAB IS EFFECTIVE AND SAFE FOR THE TREATMENT OF BULLOUS PEMPHIGOID.

Imagen Dr. Agustín España Alonso, Departamento de Dermatología
Dr. Agustín España Curriculum
Director Dermatology Department
Navarre headquarters
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID. IMMUNOTHERAPY
  • Code EudraCT: 2019-003520-20
  • Protocol number: R668-BP-1902
  • Promoter: Regeneron Pharmaceuticals, Inc.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION